Mathiesen E B, Ahlbom A, Bermann G, Lindgren J U
Department of Orthopaedic Surgery, Karolinska Institute, Huddinge University Hospital, Sweden.
J Bone Joint Surg Br. 1995 May;77(3):345-50.
The incidence of cancer after hip replacement was studied in the 1.6 million inhabitants of Stockholm County, Sweden. A cohort of 10,785 individuals who had had hip replacement between 1974 and 1988 was followed from the date of operation to the first malignant tumour, to death, or to the end of 1989. The follow-up was based on 58,437 person-years at risk as calculated from information obtained by record-linkage with the National Cancer Registry and the National Cause-of-Death Register. The Standardised Morbidity Ratio (SMR) for all cancer sites, disregarding the length of follow-up, was 0.96 (95% CI 0.90 to 1.03). For lymphoma and leukaemia the corresponding SMR was 0.89 (0.68 to 1.14). Our results do not support previous suggestions of an increased incidence of leukaemia and lymphoma after total hip replacement.
在瑞典斯德哥尔摩县的160万居民中，对髋关节置换术后癌症的发病率进行了研究。对1974年至1988年间接受髋关节置换术的10785名患者进行队列研究，从手术日期开始随访，直至首次发生恶性肿瘤、死亡或到1989年底。根据与国家癌症登记处和国家死因登记处记录链接获得的信息计算，随访基于58437人年的风险。不考虑随访时间长短，所有癌症部位的标准化发病比（SMR）为0.96（95%可信区间0.90至1.03）。淋巴瘤和白血病的相应SMR为0.89（0.68至1.14）。我们的结果不支持先前关于全髋关节置换术后白血病和淋巴瘤发病率增加的观点。
